Panama: These 5 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Panama
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Panama: These 5 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024" DrugPatentWatch.com thinkBiotech, 2023 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can JEVTANA KIT (cabazitaxel) generic drug versions launch?
Generic name: cabazitaxel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 19, 2023
Generic Entry Controlled by: Panama Patent 8,612,401
Patent Title: SOLVATO ACETONICO DEL DIMETOXI DOCETAXEL Y SU PROCEDIMIENTO DE PREPARACION
JEVTANA KIT is a drug marketed by Sanofi Aventis Us. There are four patents protecting this drug. Two tentatively approved generics are ready to enter the market.
This drug has ninety-six patent family members in forty-six countries. There has been litigation on patents covering JEVTANA KIT
The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cabazitaxel profile page.
When can VYZULTA (latanoprostene bunod) generic drug versions launch?
Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Panama Patent 8,620,901
Patent Title: DERIVADOS DE PROSTAGLANDINAS
This drug has fifty-three patent family members in thirty-eight countries.
See drug price trends for VYZULTA.
The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.
When can DUAVEE (bazedoxifene acetate; estrogens, conjugated) generic drug versions launch?
Generic name: bazedoxifene acetate; estrogens, conjugated
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 07, 2024
Generic Entry Controlled by: Panama Patent 8,629,101
Patent Title: POLIMORFO CRISTALINO DE ACETATO DE BAZEDOXIFENO
This drug has twenty-two patent family members in twenty countries.
See drug price trends for DUAVEE.
The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.
When can NATAZIA (dienogest; estradiol valerate) generic drug versions launch?
Generic name: dienogest; estradiol valerate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Panama Patent 8,630,901
Patent Title: PREPARADO POLIFÁSICO A BASE DE UN ESTRÓGENO NATURAL PARA LA CONTRACONCEPCIÓN
This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA
See drug price trends for NATAZIA.
The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.
When can VIZIMPRO (dacomitinib) generic drug versions launch?
Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Panama Patent 8,631,901
Patent Title: 4-FENILLAMINO-QUINAZOLIN-6-IL-AMIDAS
VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.
This drug has ninety patent family members in forty-seven countries.
See drug price trends for VIZIMPRO.
The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.